{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-098991","form_type":"8-K","ticker":"ACRS","cik":"0001557746","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2025-10-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.731501+00:00","generated_at":"2026-05-17T03:53:29.179432+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"low","headline":"Aclaris holds R&D Day presenting I&I pipeline; no specific data disclosed in filing","bullets":["R&D Day held Oct 14, 2025, focusing on immunology and inflammation (I&I) therapeutic franchises.","Presentation furnished as Exhibit 99.1; available on Investor Relations section of company website.","No financial results, clinical data, or guidance changes were included in the 8-K or exhibit snippet.","Company continues to develop pipeline for gaps in I&I diseases; no material updates provided."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-098991","json":"https://secwatch.observer/filing/0001104659-25-098991.json","markdown":"https://secwatch.observer/filing/0001104659-25-098991.md","text":"https://secwatch.observer/filing/0001104659-25-098991.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1557746/000110465925098991/0001104659-25-098991-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1557746/000110465925098991/acrs-20251014x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:53:29.179432+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}